Pharmacologic management of common gastrointestinal health problems in women

Journal of Nurse-Midwifery

Volumn 42, Issue 3, 1997, Pages 145-162

  Brucker, Mary C ^a   Faucher, Mary Ann ^a  

^a Parkland School of Nurse Midwifery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GASTROINTESTINAL AGENT; NON PRESCRIPTION DRUG;

DRUG COMBINATION; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; PATHOPHYSIOLOGY; PREGNANCY; REVIEW; WOMEN'S HEALTH;

DRUG THERAPY, COMBINATION; DRUGS, NON-PRESCRIPTION; FEMALE; GASTROINTESTINAL AGENTS; GASTROINTESTINAL DISEASES; HUMANS; PREGNANCY; WOMEN'S HEALTH;

EID: 0031135393     PISSN: 00912182     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-2182(97)00031-1     Document Type: Article

References (95)

1. Van Ness M, Gurney M, Jones D. Handbook of gastrointestinal drug therapy. Boston: Little, Brown and Co, 1995.
2. Shaw B. Primary care for women: comprehensive assessment of gastrointestinal disorders. J Nurse Midwifery 1995;40:216-30.
3. Shaw B. Primary care for women: management and treatment of gastrointestinal disorders. J Nurse Midwifery 1996;41:155-72.
4. Goyal RK, Hirano I. The enteric nervous system. N Engl J Med 1996;334:1106-15.
5. Bold RJ. Ishizuka J, Townsend CM Jr, Thompson JC. Biomolecular advances in gastrointestinal hormones. Arch Surg 1993; 128:1268-73.
6. Gilman AG, Rail TW, Nies AS, Taylor P. Goodman and Gilman's: the pharmacological basis of therapeutics. New York: McGraw Hill, 1993.
7. Windgard LB, Brody TM, Larner J, Schwartz A. Human pharmacology. St. Louis: Mosby, 1991.
8. Katzung BG. Basic and clinical pharmacology. Norwalk (CT): Appleton & Lange, 1994.
9. Kumar D, Wingate D. An illustrated guide to gastrointestinal motility. Edinburgh (UK): Churchill Livingstone, 1993.
10. Humenick SS. Lamaze body-wise birth preparation. J Perinatal Edu 1996;5:v-vii.
11. Feldman M, Cryer B, McArthur KE, Huet BA, Lee E. Effects of aging and gastritis on gastric acid and pepsin secretion in humans: a prospective study. Gastroenterology 1996:110:1043-52.
12. Craig CR. Stizel RE. Modern pharmacology. Boston: Little, Brown & Co., 1990.
13. McDougall NI. Johnston BT, Kee F, Collins JS. McFarland RJ. Natural history of reflux oesophagitis: a 10 year followup of its effect on patient symptomatology and quality of life. Gut 1996;38:481-6.
14. Richter JE. Gastroesophageal reflux: diagnosis and management. Hospital Pract 1992;27:59-66.
15. Marshall JB. Severe gastroesophageal reflux disease: medical and surgical options for long-term care. Postgrad Med 1995;97:98-106.
16. Feidma M. Comparison of the effects of over-the-counter famotidine and calcium carbonate antacid on postprandial gastric acid. JAMA 1996;275:1438-41.
17. Mortensen L, Charles P. Bioavailability of calcium supplements and the effect of vitamin D: comparisons between milk, calcium carbonate, and calcium carbonate plus vitamin D. Am J Clin Nutr 1996;63:354-7.
18. Lewis J. A pharmacological approach to gastrointestinal disorders. Baltimore: Williams & Wilkins. 1993.
19. Barton JR, Riely CA, Sibai BM. Baking soda pica mimicking preeclampsia. Am J Obstet Gynecol 1992:167:98-9.
20. Shindelbeck NE. Klauser AG, Voderholzer WA, Muller-Lissner SA. Empiric therapy for gastroesophageal reflux disease. Arch Intern Med 1995; 155:1808-12.
21. Hui WM. Lam SK. Lok AS, Ng MM, Lai CL. Maintenance therapy for duodenal ulcer: a randomized controlled comparison of seven forms of treatment. Am J Med 1992;92:265-74.
22. Yeomans ND, Brimblecombe RW, Elder J, Heatley RV, Misiewicz J, Northfield T. Pottage A. Effects of acid suppression on microbial flora of upper gut. Dig Dis Sciences 1995;40(Suppl 2):81S-95S.
23. Smallwood RA. Berline RG, Castognoli N. et al. Safety of acidsuppressing drugs. Dig Dis Sciences 1995;40(Suppl 2):63S-80S.
24. Atanassaoff PG, Brull SJ, Weiss BM, Landefeld K, Alton E, Rohling R. The time course of gastric pH changes induced by omeprazole and ranitidine: a 24 hour dose-response study. Anesthesia Analg 1995:80:975-9.
25. Collen MJ. Wirshup JF. Ranitidine therapy in patients with idiopathic gastric acid hypersecretion: a prospective study. Dig Dis Sciences 1995:40:1687-90.
26. Escolano F, Sierra P. Ortiz JC, Cabrera JC. Castano J. The efficacy and optimum time of administration of ranitidine in the prevention of the acid aspiration syndrome. Anesthesia 1996:51:182-4.
27. Strom B, Carson JL. Schinnar R. Shaw M. Is cimetidine associated with neutropenia? Arn J Med 1995:99:282-90.
28. Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 1996:334:1435-9.
29. Singh G, Fries JF. Famotidine to prevent peptic ulcer caused by NSAIDs [letter]. N Engl J Med 1996:335:1322.
30. Castell DO. Pill esophagitis: the case of alendronate. N Engl J Med 1996:335:1058-9.
31. Lieberman UA. Esophagitis and alendronate [letter]. N Engl J Med 1996:335:1069-70.
32. Lawrence RA. Breastfeeding: a guide for the medical profession St. Louis: Mosby, 1994.
33. Stein JH. Internal medicine. St. Louis: Mosby, 1994.
34. McQuaid KR, Isenberg J. Medical therapy of peptic ulcer disease. Surg Clin North Am 1992; 72:285-316.
35. Rakel R. Textbook of family medicine. Philadelphia: WB Saunders, 1996.
36. Sherris JC. Medical microbiology: an introduction to infectious diseases. 2nd ed. New York: Elsevier. 1990.
37. Milne R, Logan RP, Harwood D, Misiewicz JJ, Forman D. Helicobacter pylori and upper gastrointestinal disease: a survey of gastroenterologists in the United Kingdom. Gut 1995;37:314-8.
38. Soil A. Consensus conference: medical treatment of peptic ulcer disease practice guidelines from American College of Gastroenterology. JAMA 1996;275:622-9.
39. Hansson L-E. Nyren O. Hsing A, et al. The risk of stomach cancer in patients with gastric or duodenal ulcer disease. N Engl J Med 1996:335:242-9.
40. Parsonnet J. Helicobacter pylori in the stomach: a paradox unmasked. N Engl J Med 1996;335:278-9.
41. Kuipers EJ. Lundell L, Klinkenberg-Knol EC, et al. Atrophie gastritis and Hehcobacteri pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996:334:1018-22.
42. Laine LA. Helicobacter pylori and complicated ulcer disease. Am J Med 1996:100:525-75.
43. Bianchi Porro G, Parente F, Lazzaroni M. Short and long term outcome of Helicobacter pylori positive resistant duodenal ulcers treated with colloidal bismuth subcitrate plus antibiotics or sucralfate alone. Gut 1993;34:466-9.
44. Moore RA. Helicobacter pylori and peptic ulcer: a systematic review of effectiveness and an overview of the economic benefits of implementing what is known to be effective. Oxford: Pain Relief Research Unit 1995;vii:37.
45. Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med 1995:333:984-91.
46. Talley NJ. A critique of therapeutic trials in He/icobacter py/ori-positive functional dyspepsia. Gastroenterology 1994: 106:1174-83.
47. Sung JJ, Chung SC, Ling TK, Suen R. Leung VK, Lau JY, et al. Dual therapy versus triple therapy for Helicobacter pylori-associated duodenal ulcers. Dig Dis Sci 1996:41:453-7.
48. Sung JJ, Chung SC, Ling TK, et al. Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. N Engl J Med 1995;332:139-42.
49. Hosking SW. Ling TK, Chung SC, et al. Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: randomised controlled trial. Lancet 1994:343:508-10.
50. Dresner D, Coyle W, Nemec R, Peterson R, Duntemann T, Lawson JM. Efficacy of ciprofloxacin in the eradication of Heticobacter pylori. South Med J 1996;89:775-8.
51. Fedotin MS. Helicobacter pylori and peptic ulcer disease: reexamining the therapeutic approach. Postgrad Med 1993:94:38-40.
52. Eriksson S. Langstrom G. Rikner L. Carlsson R, Raesdal J. Omeprazole and h-2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis Eur J Gastroenterol Hepatol 1995:7:467-75.
53. Hirschowitz B, Keeling D, Lewin M, et al. Pharmacological aspects of acid secretion. Dig Dis Sci 1995;40(Suppl 2):3S-23S.
54. Robinson M. Prokinetic therapy for gastroesophageal reflux disease. Am Fam Phys 1995:52:957-62.
55. Mertz-Nielson A. Hillingso J, Bukhave K, Rask-Madsen J. Omeprazole promotes proximal duodenal mucosal bicarbonate secretion in humans. Gut 1996;38:6-10.
56. Mears JM. Kaplan B. Proton pump inhibitors: new drugs and indications. Am Fam Phys 1996:53:285-92.
57. Harding SM, Richter JE, Guzzo MR, Schan CA, Alexander RW, Bradley LA. Asthma and gastroesophageal reflux: acid suppressive therapy improves asthma outcome. Am J Med 1996; 100:395-405.
58. Bate CM, Booth SW. Crowe JP. et al. Omeprazole 10 mg or 20 mg once daily in the prevention of recurrence of reflux esophagitis. Gut 1995:36:492-8.
59. Di Mario F, Battaglia G, Leandro G, Grasso G, Vianello F. Vigneri S. Short-term treatment of gastric ulcer: a meta-analytical evaluation of blind trials. Dig Dis Sei 1996;41:1108-31.
60. Sorensen HT, Rasmussen HH, Balslev 1, et al. Effect of omeprazole and sucralfate on prepyloric gastric ulcer: a double blind comparative trial and one year follow up. Gut 1994:35:837-40.
61. Hunt RH. Cederberg C, Dent J, et al. Optimizing acid suppression for treatment of acid-related diseases. Dig Dis Sci 1995;40(Suppl 2):24S-49S.
62. Vigneri S, Termini R. Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995:333:1106-10.
63. Shiba S, Sugiura K. Ebata A, Kagaya T, Romori G, Marumo F, Sato C. Hyponatremia with consciousness disturbance caused by omeprazole administration: a case report and literature review. Dig Dis Sci 1996:41:1615-7.
64. Jablonska M. Healing of gastric body ulcer with gastroprotective versus antisecretory treatment. Dig Dis Sci 1995:40:2016-8.
65. Maier RV, Mitchell D, Gentilello L. Optimal therapy for stress gastritis. Ann Surg 1994;220:353-60.
66. Banerjee S, El-Omar E, Mowat A, et al. Sucralfate suppresses Helicobacter pylori infection and reduces gastric acid secretion by 50% in patient with duodenal ulcers. Gastroenterology 1996; 110:717-24.
67. Kummer AF, Johnston DA, Marks IN, Young GO, Tigler-Wybrandi NA, Bridger SA. Changes in noctural and peak acid outputs after duodenal ulcer healing with sucralfate or ranitidine. Gut 1992;33:175-8.
68. Lentz S, Barrett RJ, Homesley HD. Topical sucralfate in the treatment of vaginal ulceration. Obstet Gynecol 1993;81(Pt 2):869-71.
69. Raskin JB, White RH, Jackson JE, Weaver AL, Tindall EA, Lies RB, Stanton DS. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med 1995; 123:344-50.
70. Mertz-Nielsen A, Eskerod O, Bukhave K, Rask-Madsen J. Misoprostol inhibits gastric mucosal release of endogenous prostaglandin E2 and thromboxan B2 in healthy volunteers. Gut 1995:36:511-5.
71. Harari D, Gurwitz JH, Avorn J, Borhn R, Minaker KL. Bowel habit in relation to age and gender: findings from the National Health Interview Survey and clinical implications. Arch Intern Med 1996; 156:315-20.
72. Robinson M, Lanza F, Avner D, Haber M. Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole: a randomized, double-blind placebo-controlled trial. Ann Intern Med 1996:124:859-67.
73. Corbett JV, Yaros PS. Update on metoclopramide (Reglan). MCN 1994; 19:296.
74. Stuart JC, Ran AF, Rowbottom SJ, Yau G, Gin T. Acid aspiration prophylaxis for emergency caesarean section. Anaesthesia 1996:51:415-21.
75. Shroeder JA. The effect of intravenous ranitidine and metroclopramide on behavior, cognitive function and affect. Anesthesia Analg 1994:78:359-64.
76. Olson KR. Poisoning and drug overdose. Norwalk (CT): Appleton & Lange, 1994.
77. Mittun M, Oberg B. Total heart block after intravenous metroclopramide [letter]. Lancet 1994;343:182-3.
78. Gardner VY, Beckwith JV, Heyneman CA. Cisapride from the treatment of chronic idiopathic constipation. Ann Pharmacother 1995:29:1161-3.
79. Cuttis TF, Abell TL. Karas JG, Runs J. Symptom improvement from prokinetic therapy corresponds to improved quality of life in patients with severe dyspepsia. Dig Dis Sei 1996;41:1369-78.
80. Barker LR, Burton JR, Zieve PD. Principles of ambulatory medicine. Philadelphia: WB Saunders, 1995.
81. Theoharides TC. Essentials of pharmacology. Boston: Little, Brown & Co, 1995.
82. Bonis PA. Norton RA. The challenge of the irritable bowel syndrome. Am Family Phys 1996;53:1229-36.
83. Hanauer SB. Inflammatory bowel disease. N Engl J Med 1996:334:841-8.
84. Hirschfeld S, Clearfield HR. Pharmacologie therapy for inflammatory bowel disease. Am Fam Phys 1995;51:1971-5.
85. Farr M. Bacon PA. How and when should combination therapy be used? The role of an anchor drug. Br J Rheumatol 1995; 34 Suppl 2:100-3.
86. Capell HA. Clinical efficacy of sulphasalazine: a review. Br J Rheumatol 1995;34 Suppl 2:35-9.
87. Cronstein BW. The antirheumatic agents sulphasalazine and methotrexate share an anti-inflammatory mechanism. Br J Rheumatol 1995;34 Suppl 2:30-2.
88. Smedegard G, Bjork J. Sulphasalzaine: mechanism of action in rheumatoid arthritis. Br J Rheumatol 1995;34 Suppl 2:7-15.
89. Young WF Jr, Bivins HG. Evaluation of gastric emptying using radionuclides: gastric lavage versus ipecac-induced emesis. Ann Emergency Med 1993;22:1423-7.
90. Wrenn R. Rodewald L, Dockstader L. Potential misuse of ipecac. Ann Emergency Med 1993;22:1408-12.
91. Jewell D, Young G. Treatments for nausea and vomiting in early pregnancy. Cochrane Library 1996;3. CD rom.
92. Figg WD, Graham CL, Hak LJ, Dukes GE. Ondansetron: a novel antiemetic agent. Southern Med J 1993:86:497-502.
93. Joslyn AF. Ondansetron: clinical development for postoperative nausea and vomiting. Current studies and future directions. Anaesthesia 1994;49 Suppl:34-7.
94. Morrow GR, Hickok JT, Rosenthal S. Progress in reducing nausea and emesis: comparisons of Ondansetron (Zofran). granisetron (Rytril), and tropisetron (Navaban). Cancer 1995;76:343-57.
95. Watcha MF, White PF. Postoperative nausea and vomiting: its etiology, treatment and prevention. Anesthesiology 1992;77:162-84.